A message from the CEO of oleander medicine maker Phoenix Biotech

[Guest guest]

In response to one of our members pleas for further proof a message

was forwarded to Crandell Addington, CEOt of Phoenix Biotech. Here is

his reply:

 

Good morning, all:

 

We have an agent in Phase I Clinical Trials at M.D.Anderson Phase I

Clinic currently. You can look it up on www.clinicaltrials.gov by

using PBI-05204 as the agent. " PBI " identifying Phoenix Biotechnology,

Inc. You can see the details there. It is administered in capsular

form, not as a " pill " such as you might associate with the common form

of aspirin.

 

This agent is a supercritical extract of Nerium Oleander for which we

have received a Notice of Allowance from the USPTO. The principal

cardiac glycoside of this extract is oleandrin, although it does

contain other molecules that suggest in vitro that they are

synergistic with the oleandrin.

 

The year 2000 Phase I Clinical Trial of Anvirzel (published) does note

three patients with disease stabilization. This Trial was suspended

when the bolus became to voluminous for the intramuscular route of

administration to continue. As I recall, it did not approach its

protocol for MTD (maximum tolerated dose without serious adverse

advents) that is the primary endpoint of all Phase I Clinical Trials.

(Joe Nester of Nerium Biotechnology can give you more details.) So,

the disease stabilization suggests that increased dose levels might

have had an even more therapeutic result.

 

I have a friend who was diagnosed with terminal gastronoma almost six

years ago. He used Anivrzel as adjuvant therapy while receiving the

conventional " cocktail " at the pancreatic clinic at M.D.Anderson

Cancer Center. He continues to self-administer Anvirzel to this day,

and has not received any conventional chemotherapy in years. He

doesn't mind talking about it. Let me know if you want to talk with him.

 

There is a recent published peer-reviewed article by Dr.Newman and

others of cardiac glycosides and the science relative to their use in

tumor therapy.

 

Hope this helps.

 

Have a nice day.

Crandell Addington

CEO Phoenix Biotechnology, Inc.